← 返回

固有淋巴细胞在癌症发生和免疫治疗中的作用

英文原题:The Role of Innate Lymphoid Cells in Cancer Development and Immunotherapy.

查看英文原题

The Role of Innate Lymphoid Cells in Cancer Development and Immunotherapy.

PubMed 2022/04/26(内容时间) Front Cell Dev Biol Q1 · IF 5.3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

固有淋巴样细胞(ILCs)是一类新近才发现的难以捉摸的固有免疫细胞。其组织驻留性和依赖性使其成为一类连接适应性免疫系统和固有免疫系统的特殊细胞群。由于ILCs的异质性,其命名和分类一直具有挑战性。目前公认的ILCs分类将这些细胞分为两类,包括细胞毒性ILCs和辅助性ILCs。肿瘤微环境对免疫细胞往往具有敌意。重塑微环境并调节其他免疫细胞——由ILCs实现——可以增强抗肿瘤效应。ILCs如何在肿瘤微环境中调节其他免疫细胞仍有待阐明。本文综述了目前对ILCs在肿瘤微环境中作用的认识。在PDAC中,ILCs招募CD8阳性T细胞和记忆T细胞,ILCs还能够帮助CD108阳性B细胞向肿瘤部位迁移。在NSCLC中,ILC3s被观察到帮助驻留巨噬细胞增强针对癌细胞的黏液免疫。随后我们重点讨论细胞因子和免疫检查点通路在ILCs中的作用及其在免疫治疗中的意义。

展开英文摘要原文

Innate Lymphoid Cells (ILCs) are an elusive type of innate immune cell that was only discovered recently. Their tissue residency and dependency makes them a niche group of cells that bridge the adaptive and innate immune system. The nomenclature and classification of ILCs have been challenging due to their heterogeneity.

The currently agreed ILC classification splits the cells into two categories including cytotoxic and helper ILCs. The tumour microenvironment is often hostile for immune cells. Remodeling the microenvironment and regulating other immune cells-achieved by ILCs-can enhance anti-tumor effects. How ILCs regulate other immune cells in the tumor microenvironment remains to be understood.

Here we review current understanding of the role of ILCs in the tumor microenvironment. ILCs recruit CD8 positive T and memory T cells in PDAC, ILCs are also able to help CD108 positive B cells migrate toward tumour locations. In NSCLC, ILC3s are seen helping resident macrophages enhancing the mucus immunity to cancer cells.

We then highlight the roles of cytokines and immune checkpoint pathways in ILCs and its implication in immunotherapy.

论文信息

作者
Sugimura R、Wang CY
单位
School of Biomedical Sciences, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.Hong Kong
文献类型
综述
期刊
Frontiers in cell and developmental biology2022
原文标识
PubMed 35557940 · DOI 10.3389/fcell.2022.803563